{"disease":{"id":"thalidomide","name":"thalidomide"},"drugs":{"marketed":[{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma - Thalidomide","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03318835","title":"Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":162,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06256627","title":"The Maintenance Treatment of \"ITIVA\" in AML Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":130,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT04273529","title":"The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"First Affiliated Hospital of Wenzhou Medical University","has_results":false},{"nct_id":"NCT06279351","title":"Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Xinqiao Hospital of Chongqing","has_results":false},{"nct_id":"NCT06985134","title":"Comparative Efficacy and Safety of Thalidomide and Sulfasalazine in Moderate to Severe Ankylosing Spondylitis: A Real-World Study From Bangladesh","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","has_results":false},{"nct_id":"NCT05525234","title":"A Study of Thalidomide in the Treatment of Refractory Uremic Pruritus","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT04273581","title":"The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"First Affiliated Hospital of Wenzhou Medical University","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}